US EditionIvonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
Ivonescimab is the only drug from a Chinese company's independent R&D on FirstWord Pharma’s top 20 list shaping the pharma industry trajectory in 2026.
- FirstWord Pharma listed Akeso, Inc. 's ivonescimab among 20 key drugs for 2026, as part of its 'Spotlight On' report released on Jan. 28, 2026.
- Akeso's ivonescimab stands out because it is a PD-1/VEGF bispecific antibody and the only drug from an independent Chinese R&D program on FirstWord Pharma's list.
- Alongside ivonescimab, the list names major assets including Gilead Sciences/Arcellx's anito-cel, Roche's Giredestrant, Eli Lilly's Kisunla, AstraZeneca/Daiichi Sankyo's Datroway, Novartis' Pelacarsen, and Moderna/Merck's intesmeran autogene.
- Akeso said the inclusion raises ivonescimab's international visibility and cautioned that forward-looking statements are subject to risks and not investment advice.
- As it advances its IO 2.0+ strategy, Akeso, Inc. is developing a pipeline of over 50 assets, including 26 clinical-stage candidates.
24 Articles
24 Articles
Ivonescimab Included in FirstWord Pharma's 'The Drugs That Will Shape 2026'
HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled 'Spotlight On: The Drugs That Will Shape 2026', providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific…
Watauga Democrat
Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
HONG KONG, Jan. 28, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key…
Coverage Details
Bias Distribution
- 59% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
